Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages 508-516

  Strassl, R ^a   Reiberger, T ^a   Honsig, C ^a   Payer, B A ^a   Mandorfer, M ^a   Grabmeier Pfistershammer, K ^b   Rieger, A ^b   Kundi, M ^a   Grundtner, P ^c   Peck Radosavljevic, M ^a   Popow Kraupp, T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c Gilead Sciences   (Austria)

Author keywords

HBeAg quantification; HBsAg quantification; HBV DNA; HIV HBV coinfection; nucleos(t)ide analogue

Indexed keywords

EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRAL CLEARANCE; BLOOD; COMPLICATION; DRUG COMBINATION; HEPATITIS B, CHRONIC; LONGITUDINAL STUDY; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902285405     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12175     Document Type: Article

References (27)

1. WHO. Progress Report 2011: Global HIV/AIDS Response. Available at: http://www.who.int/hiv/pub/progress-report2011/en/index.html (accessed 11 September 2012).
2. Alter MJ,. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (Suppl. 1): S6-S9.
3. Thio CL, Seaberg EC, Skolasky R Jr, et al,. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349): 1921-1926.
4. Belongia EA, Costa J, Gareen IF, et al,. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25 (2): 1-29.
5. Werle-Lapostolle B, Bowden S, Locarnini S, et al,. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126 (7): 1750-1758.
6. Volz T, Lutgehetmann M, Wachtler P, et al,. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133 (3): 843-852.
7. Chan HL, Wong VW, Tse AM, et al,. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5 (12): 1462-1468.
8. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49 (4): 1141-1150.
9. Tseng TC, Liu CJ, Su TH, et al,. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141 (2): 517-525, 25e1-2.
10. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C,. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther 2011; 16 (2): 199-205.
11. Wursthorn K, Jung M, Riva A, et al,. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52 (5): 1611-1620.
12. Chan HL, Wong GL, Tse CH, Chan HY, Wong VW,. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204 (3): 408-414.
13. Kosi L, Reiberger T, Payer BA, et al,. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 2012; 19 (11): 801-810.
14. Fung J, Lai CL, Young J, et al,. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106 (10): 1766-1773.
15. Gish RG, Chang TT, Lai CL, et al,. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009; 17 (1): 16-22.
16. Cai W, Xie Q, An B, et al,. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48 (1): 22-26.
17. Lee JM, Ahn SH, Kim HS, et al,. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53 (5): 1486-1493.
18. Marcellin P, Bonino F, Lau GK, et al,. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136 (7): 2169-2179.e1-4.
19. Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49 (4): 1151-1157.
20. Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al,. HBSAG decline and clearance during long-term tenofovir therapy in patients co-infected with hepatitis B and human immunodeficiency virus. J Infect Dis 2012; 206 (6): 974-980.
21. Maylin S, Boyd A, Lavocat F, et al,. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012; 26 (8): 939-949.
22. Moucari R, Lada O, Marcellin P,. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7 (6): 633-636.
23. Lin CL, Kao JH,. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 (Suppl. 1): 123-130.
24. Chan HL, Thompson A, Martinot-Peignoux M, et al,. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55 (5): 1121-1131.
25. Reijnders JG, Rijckborst V, Sonneveld MJ, et al,. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54 (3): 449-454.
26. Thompson AJ, Nguyen T, Iser D, et al,. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51 (6): 1933-1944.
27. Jaroszewicz J, Reiberger T, Meyer-Olson D, et al,. Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. PLoS ONE 2012; 7 (8): e43143.